• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恶性淋巴瘤克隆进化过程中p53和c-myc的改变。

Alterations of p53 and c-myc in the clonal evolution of malignant lymphoma.

作者信息

Chang H, Benchimol S, Minden M D, Messner H A

机构信息

Ontario Cancer Institute, University of Toronto, Ontario, Canada.

出版信息

Blood. 1994 Jan 15;83(2):452-9.

PMID:8286743
Abstract

We derived the lymphoma cell lines OCI-Ly 13.1 and OCI-Ly 13.2 from a patient with non-Hodgkin's lymphoma at the time of presentation and during chemotherapy-resistant relapse. These lines were of T-cell phenotype and contained the identical T-cell receptor beta-chain rearrangement, indicating that both lines were members of the same malignant clone. The lines differed in their growth characteristics; OCI-Ly 13.1 grew slowly and required growth factors for colony formation, whereas OCI-Ly 13.2 grew rapidly and formed colonies without addition of growth factors. To test whether or not these biologic differences were associated with specific genetic changes, we evaluated the status of the c-myc and p53 genes of both cell lines. The p53 and c-myc genes of OCI-Ly 13.1 were in germline configuration and produced normal-sized transcripts. The p53 protein expressed in OCI-Ly 13.1 was recognized by the anti-p53 monoclonal antibody, PAb240, indicating a conformation typical of p53 proteins expressed by p53 alleles containing a missense mutation. However, sequencing studies of the entire p53 coding region did not reveal any point mutations. In contrast, the cell line OCI-Ly 13.2 contained structural abnormalities of both the c-myc and p53 genes. In addition, one of the p53 alleles was lost as determined by a cDNA probe for the p53 gene (17p 13.1) and the YNZ22.1 probe (17p 13.3). These changes resulted in the absence of p53 protein and mRNA in OCI-Ly 13.2 as detected by immunoprecipitation and Northern blot analysis, respectively. They may be a reflection of disease progression and may be associated with the altered behavior of the malignant cell population within the patient and in vitro.

摘要

我们在一名非霍奇金淋巴瘤患者初诊时以及化疗耐药复发期间,分别获取了淋巴瘤细胞系OCI-Ly 13.1和OCI-Ly 13.2。这些细胞系具有T细胞表型,且含有相同的T细胞受体β链重排,表明这两个细胞系均为同一恶性克隆的成员。这两个细胞系在生长特性上存在差异;OCI-Ly 13.1生长缓慢,形成集落需要生长因子,而OCI-Ly 13.2生长迅速,不添加生长因子即可形成集落。为了检测这些生物学差异是否与特定的基因变化相关,我们评估了两个细胞系中c-myc和p53基因的状态。OCI-Ly 13.1的p53和c-myc基因呈种系构型,产生正常大小的转录本。OCI-Ly 13.1中表达的p53蛋白可被抗p53单克隆抗体PAb240识别,表明其构象为含有错义突变的p53等位基因所表达的p53蛋白的典型构象。然而,对整个p53编码区的测序研究未发现任何点突变。相比之下,细胞系OCI-Ly 13.2的c-myc和p53基因均存在结构异常。此外,通过p53基因(17p 13.1)的cDNA探针和YNZ22.1探针(17p 13.3)检测发现,其中一个p53等位基因缺失。这些变化导致OCI-Ly 13.2中分别通过免疫沉淀和Northern印迹分析检测不到p53蛋白和mRNA。它们可能反映了疾病的进展,并且可能与患者体内及体外恶性细胞群体行为的改变有关。

相似文献

1
Alterations of p53 and c-myc in the clonal evolution of malignant lymphoma.恶性淋巴瘤克隆进化过程中p53和c-myc的改变。
Blood. 1994 Jan 15;83(2):452-9.
2
p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines.人类非霍奇金淋巴瘤细胞系中的p53突变、c-myc和bcl-2重排
Leuk Lymphoma. 1995 Sep;19(1-2):165-71. doi: 10.3109/10428199509059672.
3
Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations.成人T细胞白血病/淋巴瘤中癌基因和肿瘤抑制基因的结构与功能分析显示p53频繁突变。
Blood. 1992 Dec 15;80(12):3205-16.
4
Intraclonal molecular heterogeneity suggests a hierarchy of pathogenetic events in Burkitt's lymphoma.克隆内分子异质性提示伯基特淋巴瘤发病机制事件存在层级关系。
Ann Oncol. 1997 Oct;8(10):987-94. doi: 10.1023/a:1008265304712.
5
Molecular features of primary mediastinal B-cell lymphoma: involvement of p16INK4A, p53 and c-myc.原发性纵隔B细胞淋巴瘤的分子特征:p16INK4A、p53和c-myc的参与情况
Br J Haematol. 1999 Oct;107(1):106-13. doi: 10.1046/j.1365-2141.1999.01678.x.
6
HOXD3 Up-regulating KDM5C Promotes Malignant Progression of Diffuse Large B-Cell Lymphoma by Decreasing p53 Expression.HOXD3 通过降低 p53 表达促进弥漫性大 B 细胞淋巴瘤的恶性进展。
Balkan Med J. 2022 Jan 25;39(1):30-38. doi: 10.5152/balkanmedj.2021.21068. Epub 2021 Dec 20.
7
Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines.尿路上皮癌细胞系中肿瘤抑制基因的失活及c-myc基因的失调。
Urol Res. 1995;23(5):293-300. doi: 10.1007/BF00300017.
8
Molecular characterization of CD30+ anaplastic large-cell lymphoma: high frequency of c-myc proto-oncogene activation.CD30阳性间变性大细胞淋巴瘤的分子特征:c-myc原癌基因高频激活
Blood. 1994 Jun 15;83(12):3581-90.
9
Constitutive production of the interleukins IL-5 and IL-6 by the lymphoma cell line OCI-Ly 17 derived from a patient with malignant lymphoma and hypereosinophilia.
Leuk Lymphoma. 1992 Sep;8(1-2):97-107. doi: 10.3109/10428199209049823.
10
Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines.人类白血病T细胞系中p53肿瘤抑制基因的频繁突变。
Mol Cell Biol. 1990 Oct;10(10):5502-9. doi: 10.1128/mcb.10.10.5502-5509.1990.

引用本文的文献

1
Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia.鉴定生存素作为成人B细胞急性淋巴细胞白血病免疫治疗的一个有前景的靶点。
Oncotarget. 2017 Dec 17;9(3):3853-3866. doi: 10.18632/oncotarget.23380. eCollection 2018 Jan 9.
2
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.PI3K-δ、γ 抑制剂 duvelisib 在 T 细胞淋巴瘤的 1 期临床试验和临床前模型中的活性。
Blood. 2018 Feb 22;131(8):888-898. doi: 10.1182/blood-2017-08-802470. Epub 2017 Dec 12.
3
Progressive tumor growth-associated altered tumor microenvironment: implications in a tumor stage-dependent modulation in survival of a murine T cell lymphoma.
肿瘤进展相关的肿瘤微环境改变:对小鼠T细胞淋巴瘤生存的肿瘤分期依赖性调节的影响
J Cancer Res Clin Oncol. 2009 Aug;135(8):1015-24. doi: 10.1007/s00432-008-0537-5. Epub 2009 Jan 6.
4
Identification of tumour-associated and germ line p53 mutations in canine mammary cancer.犬类乳腺癌中肿瘤相关及种系p53突变的鉴定
Br J Cancer. 1999 Oct;81(3):409-15. doi: 10.1038/sj.bjc.6690709.
5
Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene.氯尼达明可独立于p53基因诱导耐药细胞凋亡。
J Clin Invest. 1996 Sep 1;98(5):1165-73. doi: 10.1172/JCI118900.